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Abstract 
Transplantation between humans is today an accepted treatment for several diseases. 
The lack of human donors is however the major obstacle against widening the indica­
tions for organ transplantation. Transplantation of t issue between different species e.g. 
xenotransplantation, may be one solution to the problem. Different animal species have 
been suggested, but the pig is to day considered as the most suitable donor. The prima­
ry barrier to pass when transplanting between species is the hyperacute rejection which 
appears when the organ is connected to the recipient's blood stream. This is caused by 
preformed natural antibodies in the recipient, which react with carbohydrate antigens 
exposed on the endothelial cells of blood vessels in t he transplanted organ. A galactose 
linked in an al,3 linkage to another galactose (Galal,3Gal) as a terminal carbohydrate 
sequence is the major target for the human antibodies. 
We have studied and characterised the expression of carbohydrate structures in dif­
ferent porcine organs. The structural elucidation of t he cell surface carbohydrates was 
made with antibodies and different mass spectrometric and/or nuclear magnetic reso­
nance spectroscopy methods. 
The development of improved, more sensitive, methods for carbohydrate analysis 
have made it possible to analyse carbohydrates in small amounts of tissue. By u sing the 
GC/MS technique we were allowed to look for differences in carbohydrate expression 
in small tissue specimens from pig small intestine, heart, spleen, liver, salivary gland, kid­
ney and lung. The advantages of the technique is the small sample amount needed, the 
sensitivity and the speed of analysis, a nd the screening pattern obtained, showing both 
qualitative and quantitative differences in the analysed mixtures of oligosaccharides. By 
using the LC"on-flow"NMR technique, we got the possibility to separate, and at the 
same time analyse single carbohydrates, e.g. glycolipids, in a mixture from pig lung. This 
is the first time this method has been used for native glycolipids. 
The enzymes involved in carbohydrate chain biosynthesis in pig small intestine were 
also studied. The biosynthetic products from "in vitro" experimental studies with pre­
pared enzymes were compared to the carbohydrate expression "in vivo", produced by 
the same enzymes. The enzymes were shown to accept a variety of precursor carbohy­
drate chains in the "in vitro" situation compared to the "in vivo" situation where one pre­
cursor chain type was dominant. 
It is still a long way to go before the mysteries of xenotransplantation are solved. By 
characterising the carbohydrates on the cell surfaces in organs of interest, we have taken 
a small step towards a complete understanding of the mechanisms of xenotransplant 
rejection. 
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Ge pengar till ett institut 
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och få et t pris ur kungens hand 
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eller sätt en värld i brand 
Vi kommer alltid att leva, 
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Ur "Vi kommer aldrig att dö" 
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i. Blood group ABH 
cell surface carbohydrates 
Carbohydrate 
Blood g roup ABH active oligosaccharides are expres­
sed in cells, tissues and body fluids. At the cell surface 
they are bound to the cell membranes, linked by either 
lipids or proteins as glycolipids or glycoproteins. 
Carbohydrates can also exist as free molecules in the 
body fluids. 
Glycosphingolipids 
Glycosphingolipids (GSL) are composed of a carbohy­
drate part and a lipid part, which anchors the molecu­
le into cell membranes. The carbohydrate part can 
range in size from a single residue to more than 60 
sugar residues and can consist of a variety of different 
sugars, each of which can be attached to each other in 
a variety of ways (linkage and anomerity). The com­
plex oligosaccharide chain of GSLs can be either line­
ar or branched and carry blood group determinants. 
The lipid part, consisting of a long chain base, sphing-
osine, and an amide bonded fatty acid, is also known as 
ceramide, and shows significant heterogeneity due to 
variation in carbon chain length, number of double 
bonds, methyl branching and hydroxyl groups [1, 2], 
Although the lipid tail is not directly involved in deter­
mining the blood group epitope carried by the carbo­
hydrate chain, it can influence the steric presentation 
of the epitope at the cell surface [3], The GSL can be 
neutral or acidic, the latter ones containing sulphate 
(e.g. sulphatides) or sialic acid (e.g. gangliosides). 
Ceramide 
CH2OH 
O —CH. 
OH 
non-hydroxy 24:0 fatty acid 
v/ 
dl 8:1 sphingosine 
Fig. 1 A schematic 
formula of a simple 
GSL monoglycosyl-
ceramide. The GSL 
consists of a car­
bohydrate and a 
ceramide part. The 
ceramide part in 
this example 
contains a non-
hydroxy 24:0 fatty 
acid and a dihy-
droxy d18: 1 long 
chain base (sphing­
osine). 
Glycoproteins 
Carbohydrates bound to proteins, e.g. glycoproteins, 
can be linked to the sugar chain moiety through an N-
acetylglucosamine to an asparagine residue (N-linked) 
[4] or through an N-acetylgalactosamine to a serine or 
a th reonine residue (O-linked) [5-7], The complexity 
of t he carbohydrate chain is like that of the ceramide 
bound carbohydrate [8], Although, unlike ceramide 
bound glycoconjugates, more than one species of oli­
gosaccharide chain may exist on the same protein. 
The N-linked glycoproteins contain a common pen­
tasaccharide core structure (Manal,6(Manocl,3)Man 
ßl,4GlcNAcßl,4GlcNAc-Asn) which is extended to 
form three different forms of oligosaccharides, one 
complex type which is often terminally sialylated and 
therefore gives the structure a net negative charge, a 
hybrid type and a high mannose type [4], Important 
N-liked glycoproteins are e.g. the interleucin lß(IL-lß) 
[9] and interleucin-6 (IL-6) [10]. 
The O-linked oligosaccharides show four major 
core structures. The O-linked glycoproteins consists 
either of simple disaccharide chains bound to the 
hydroxyl oxygen of serine or threonine (Galßl,3Gal 
NAcal-O-Ser/Thr) or are more complex chains with 
an extension or branching of lactosamine structures [6, 
7], These oligosaccharides are expressed in e.g. the gas­
trointestinal tract, lung and glandular tissue [5], Blood 
group reactivity has been found on O-linked glycopro­
tein [11]. O-liked N-acetylglucosamines have also 
been found in cytoplasmic and nucleoplasms glyco­
proteins involved in the regulation of phosphorylation 
[12, 13], 
The proteoglycans are glycoproteins with a domina­
ting glycan part, compared to the glycoproteins, which 
have a dominant protein part. The proteoglycans con­
sist of a repeating unit of disaccharides, which also can 
be sulphated. The carbohydrate part can be linked to 
the serine via xylose [14]. 
Phenotypes 
The blood group phenotype of an individual is deter­
mined by the structures of the carbohydrates present 
at the terminus of the oligosaccharide chain. A variety 
of different chain types can be found on glycoconjuga­
tes and they can be grouped/named according to their 
precursor chains (Table l).This nomenclature recogni­
ses the types of sugars, anomerity and linkage position 
of the terminal saccharides in the chain. ABH blood 
group determinants can reside on a variety of these dif­
ferent chain types with each representing a d ifferent 
ABH structure, which may show a species- [15-18], 
tissue- [19] and cell- [20] specific distribution. For 
example, type 1 ABH antigens are only found in indi­
viduals who are blood group secretors, while the type 
3 A antigen is generally only found on the red cells of 
individuals of the A, phenotype, and the A type 4 anti­
gen is stro ngly expressed in kidney. The structure of 
the chain bearing the blood group determinant also 
influences the steric presentation of the epitope at the 
cell surface, which thus can be recognised by specific 
antibodies [21]. 
In the gastrointestinal tract, GSLs bearing blood 
group determinants are predominantly short (4 to 7 
sugars in length), while those on the red cell, bearing 
similar blood group determinants (albeit on different 
chain types) are predominantly large branched struc­
tures (30-60 sugars) [22,23], 
Type 1 Galß 1,3GlcNAcß 1 -R 
Type 2 Galß l,4GlcNAcß 1 -R 
Type 3 Gakxl,3GalNAcßl-R 
Type 4 Galßl,3GalNAcßl-R 
Type 5 Galßl,3Galßl-R* 
Type 6 Galßl,4Glcßl-R 
Table 1. Structures of possible disaccharide precursors 
[24], (* not described in humans). 
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Histo-blood group expression 
At the beginning of this century, Landsteiner discove­
red the ABO blood group system [25], He observed 
that erythrocytes from one individual could be agglu­
tinated by serum from certain people but not from 
others. Much later, the H blood group system was defi­
ned, thereby defining the structure of the "O antigen" 
as th e precursor of A and/or B. More recently, several 
studies have shown that the expression of the blood 
group ABH antigens is n ot limited to red blood cells 
and the antigens can be found in most tissues and flu­
ids of the body. Today the term histo-blood group sys­
tem, first used by Clausen and Hakomori [23] is used 
to better describe the expression of the carbohydrate 
blood group system antigens. The histo-blood group 
antigens also show a tissue specific expression [2] and 
can be secreted in the body fluids [26-28]. Histo-blood 
group expression often shows similarities between dif­
ferent species and closer related species shows more 
similarities, e.g. humans and monkeys [29], 
Carbohydrate expression 
in different tissues 
A specific pattern of the carbohydrate expression is 
found in different organs and tissues, reflecting the 
cell-specific carbohydrate phenotypes of the cell types 
constituting a particular tissue [2, 23, 30]. Glycosyl-
transferases act on the carbohydrate chain, adding dif­
ferent monosaccharides to elongate the chain. Some of 
the transferases are shown to act on both GSL and gly­
coproteins [31]. 
The type 1 chain 
The type 1 GSL chain (Galßl,3GlcNAcßl,3Gal 
ßl,4Glcßl,lCer) is sy nthesised in ectodermal tissues 
as in t he case of small intestinal mucosa and glandular 
epithelium [2], This chain is the most common carrier 
of the Lewis and ABO antigens in body fluids and 
secretions. The type 1 chain is not synthesised in endo-
dermal tissues with exception of the non-keratinised 
oral epithelium, nor in mesodermal derived tissues. 
Type 1 chain based antigens can however be present 
on erythrocytes and lymphocytes but as a c onsequen­
ce of absorbing freely circulating GSLs from the plas­
ma. 
The secretor gene (Se) encodes an al,2 fucosyl-
transferase, which can bind a fucose residue in a al,2 
position to the terminal galactose of the type 1 chain 
e.g. lactotetra, to form H type 1 [32]. The product of 
the secretor gene is found in bodily secretions and 
seminal fluids. The gene is generally expressed in tissu­
es related to exocrine secretion of type 1 chains. 
The Lewis blood group determinants (Le) are also 
based on the type 1 chain and are present on both pro­
teins and GSLs. The Lewis gene encoded a3/4 fuco-
syltransferase adds a fucose residue in an al ,4 position 
to the subterminal N-acetyl-glucosamine of the type 1 
precursor which gives rise to the Lea antigen 
(Galßl,3(Fucal,4)GlcNAcßl,3Galßl,4Glcßl,lCer) 
[32]. If th e secretor fucosyltransferase had previously 
modified the type 1 precursor into H type 1 before the 
Lewis transferase added the subterminal fucose, the 
Leb antigen ((Fucal,2)Galßl,3(Fucal,4)GlcNAc 
ßl,3Galßl,4Glcßl,lCer) results. The secretor transfe­
rase cannot make Le'3 from Lea. The Lea and Le'3 anti­
gens predominandy exist as 5 and 6 sugar GSL's, bu t 
much larger GSLs bearing these epitope are also com­
mon [32], Lewis antigens bearing ABO determinants 
exist. If the H type 1 antigen is converted into A type 
1 the Lewis transferase is still able to add its fucose and 
a difucosylated compound antigen ALeb is formed. 
Likewise modification of B type 1 by the Lewis trans­
ferase results in the BLeb antigen. The Le'3 antigen is, 
however, not a suitable substrate for the A or B glyco-
syltransferases. 
Red cell phenotype Glycosyltransferases Major product in secretions 
ABO Lewis Le Se A B 
A, B, AB, O Let3"'3") 
- -
+/- +/- type 1 
precursor 
O LeCab-) 
- + - - H type 1 
A, B, AB Le(a"b") " + +/- +/- A type 1 
and/or 
B type 1 
A, B, AB, O LeO+b") + - +/- +/- Le" 
O Le(a-b+) + + - - Le" 
A, B, AB Le(a"b+) + + +/- +/- ALeb 
and/or 
BLeb 
The type 2 chain 
The type 2 GSL chain (Galßl,4GlcNAcßl,3Gal 
ßl,4Glcßl,lCer) is expressed in tissues of ectodermal 
and mesodermal origin, i.e. skin and erythrocytes. Type 
2 chain based ABH antigens are the predominant ABH 
antigens present on the red cells. The chain can also be 
found in some endodermal tissues together with the 
type 1 chain. The type 2 precursor can be fucosylated 
by either the H or the Se fucosyltransferases to form H 
type 2. The type 2 chain based ABH antigens in saliva 
are not formed by the H gene encoded enzyme 
(because it is not expressed in the secretory compart­
ments), but instead by the action of the secretor fuco­
syltransferase. In the gastrointestinal tract, the expres­
sion of type 2 chain based antigens is generally weak 
[33], 
In addition, the Lewis a3/4 fucosyltransferase can 
modify the type 2 precursor to form Lex (X), H type 
2 to form Le^ (Y) and A and B type 2 to form ALe^ 
(AY) and BLe^ (BY) respectively. The Lewis transfera­
se is not the only transferase capable of a3 fucosyla-
tion, and the above structures can also b e formed by 
other a3 fucosyltransferases such as FUT4, FUT5, 
FUT6 and FUT7 [34], 
The type 3 chain 
The type 3 chain (Galßl,3GalNAcal) exists in two 
major forms. One is an O-linked chain of mucin type 
[35]. The disaccharide is a part of the T/Tn 
(Galßl ,3GalNAcal -O-Ser/Thr/GalNAcal -O-
Ser/Thr) blood group system (Thomsen-Friedenreich 
antigen and related antigen). The chain is common in 
many cells and tissues, including erythrocytes, but is 
almost always substituted with a sialic acid. The sub­
stituted structure is often present in ovarian cysts and 
gastric mucosa. It is also associated with human gastric 
intestinal metaplasia and carcinomas for example in 
breast, colon, lung, kidney, ovary, and re ctum [36-38], 
The type 3 chain also exists as an extension of the 
blood group A antigen (GalNAcal,3(Fucal,2)Gal 
Table 1. The major 
blood group anti­
gens present in 
saliva in individuals 
with different ABO, 
Lewis and Secretor 
phenotype. For 
simplicity, A, B and 
AB have been 
grouped together, 
but only the A pro­
ducts are present 
when the A glyco-
syltransferase is 
present and the 
same for the B pro­
ducts. 
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ßl,3GalNAcal,3(Fucßl,2)Galßl,4GlcNAcßl,3Galß 
l,4Glcßl,lCer). This repetitive blood group A struc­
ture was first described in 1985 by Clausen et al [39). 
This extended A GSL structure, also known as A-9-3, 
represents an elongation of the A type 2 chain, first by 
the addition of a galactose, to produce the type 3 pre­
cursor, then modification by the H transferase to form 
H type 3, then glycosylation by the A] transferase to 
produce A type 3. The A2 transferase is unable to 
affect the transfer and the H type 3 precursor remains 
unsubstituted in the blood group A2 individual. 
The type 4 chain 
The type 4 chain GSL (GalNAcßl ,3Galal ,3Gal 
ßl,4Glcßl,lCer) is also referred to as globoside and 
belongs to the globo-series of GSLs. Globoside is a 
major glycolipid on erythrocyte membranes but can, 
together with other globo-series glycolipids, also be 
found in kidney, small intestine, spleen, salivary gland, 
liver and heart in different species [29], 
Blood group P related structures 
In the early days, Landsteiner and Levine identified an 
antigen in the blood which they named P. The antigen 
was later renamed to the blood group P] antigen (Gal 
al,4Galßl,4GlcNAcßl,3Galßl,4Glcßl,lCer) and is, 
together with the two other serological related antigens 
P (GalNAcßl,3Galal,4Galßl,4Glcßl,lCer) i.e. globo­
side, and P (Galal,4Galßl,4Glcßl,lCer) i.e. globotri-
aosylceramide, named the blood group P system. Other 
structures related to the system are the Globo-5 
(Galß 1,3 GalNAcßl,3Galal ,4Galß 1,4Glcßl, 1 Cer), 
globo-H (Fucal,2Galßl,3GalNAcßl,3Galal,4Gal 
ßl,4Glcßl,lCer), globo-A, also called A type 4 (Gal 
NAcal ,3 (Fucal ,2)Galßl ,3GalNAcßl ,3Galocl ,4Galß 
l,4Glcßl,lCer) and the Forssman antigen (GalNAca 
1,3 GalN Acß 1,3 Galal ,4Galß 1,4Glcß 1,1 Cer). 
The ganglio-series 
The ganglio-series of GSLs can express ABO epitopes. 
The ganglio chains can be substituted with sialic ac id 
and are in these cases called acidic GSLs or gangliosi-
des. T he GSL gangliotetraosylceramide (Galßl,3Gal 
NAcßl,4Galßl,4Glcßl,lCer) is commonly found in 
cells with neural origin [40], 
Other glycosphingolipid chains 
The glycosphingolipid chains mentioned above are the 
most commonly found chains in human and pigs. 
Other glycosphingolipid chains exist but are not dis­
cussed here. 
Biological functions and implications 
Variations of an oligosaccharide chain can be accom­
plished by different monomers (i.e. fucose, glucose, 
galactose, N-acteylgalactosamine), different carbohy­
drate sequences, changes in binding positions, bran­
ching/non-branching or binding configurations [2], All 
these variations of the carbohydrate part may potenti­
ally have an impact on the function of the GSL. Fifteen 
years ago, glycosylation of glycoproteins and GSLs was 
not believed to play any significant functional role. 
Today functions are still largely unknown, but a nu m­
ber of proteins bind to the oligosaccharide portions of 
GSLs and glycoproteins which indicate involvement in 
cell-cell recognition [41-43], leucocyte adhesion and 
recruitment (E-selectin and sialyl-Lex) [44], GSLs are 
also shown to interact in cell surface recognition events 
[45]. Glycosylation may furthermore affect the func­
tion of the cell [46], Both the extent and type of gly­
cosylation can play a role in the glycoprotein activity. 
Oligosaccharides are believed to be involved in neural 
differentiation [40], oncogenesis [47-49] and metasta­
sis [50], Many hormones are also glycosylated e.g. 
gonadotropins, LH and FSH. [51]. GSLs have been 
shown to be involved in the adhesion of bacteria, viru­
ses and toxins to cellular surfaces (microbial ligands) 
[52, 53], Carbohydrate chains can also function as the­
rapeutic targets in i.e. allergic inflammatory disorders 
[54], auto-immune rheumatic diseases [55] and in the 
hyperacute rejection during xenotransplantation, see 
below [56]. 
Variation of ABO expression during 
development and cell differentiation 
Expression of the ABO glycolipids have been shown to 
be closely related to cell differentiation phenomena 
[57]. 
Branching of linear type 2 chains can be accomplis­
hed by a Galal,6 glycosyltransferase regulated by the 
I ge ne. Before birth, there is very little expression of 
branched chains and thus the blood group ABH deter­
minants of the red cells are found on linear chains. The 
late onset of the I gene, and thus sparse expression of 
branched ABH determinants at birth, has been sugges­
ted to be an evolutionary phenomenon to reduce the 
occurrence of serious cases of ABH haemolytic disea­
ses in new-borns. The binding of an IgG anti-A antibo­
dy on to both epitopes of a branched antigen has been 
called monogamous bivalency and shown to activate 
complement more efficiently. 
Transfusion between 
individuals and species 
Blood transfusions between individuals became a rela­
tively safe procedure after Landsteiners discovery of 
the blood group ABH system. Before that, transfusions 
between individuals often resulted in acute haemolysis 
and a mortality of about 30%. 
A transfusion of blood from animals like sheep, cal­
ves and pigs does not necessarily lead to haemolysis at 
the first transfusion. A second transfusion, after boos­
ting the sparsely occurring natural antibodies, will 
though elicit a life treating condition. 
Transplantation between 
individuals and species 
Transplantation between individuals has been made 
more or less regularly since the 60's, and has increased 
in number as a consequence of successive improve­
ments in immunosuppressive regimens and graft survi­
val. Primary donor-recipient selections in orga n trans­
plantation are routinely blood group ABO matched. 
Blood group ABO incompatible organ transplantation 
is, however, feasible under special circumstances or 
actions [58], Blood group A2 to O kidney transplanta­
tion has been shown possible due to the low blood 
group A expression in kidneys in these individuals. 
Major ABO incompatibilities are also possible provi­
ded that plasmapheresis or specific absorption lowers 
isoaggutinin titres. The spleen also needs to be remo­
ved. In all cases, lon g term survival and tolerance e.g. 
accommodation [59], can be induced. 
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Xenotransplantation (transplantation between spe­
cies) has been performed through history with limited 
success [60-62], 
In recent years the realism of success for xenotrans­
plantation has gradually increased. The identification 
of the Galal,3Galßl,3 iso antigen/antibody system 
(e.g. similar to blood group ABO incompatibility in 
allotransplantation) has provided a handle for surpas­
sing the initial hyperacute barrier. Pig kidneys have 
been connected to the blood stream outside the body 
of human dialysis patients [63, 64], Human anti-pig 
antibodies were heavily depleted through extensive 
plasmapheresis and protein A absorption. In one case, 
urine was produced for 6 hours. 
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2. Methods 
GSL isolation and fractionation 
Over the years several different protocols have been 
described for isolation and purification of GSLs [65-
67], The GSL preparation and purification method 
described by Karlsson [66] was used in this thesis. 
The preparation procedure used can be summarised 
as follows; 
The chosen tissue sample was cut into small pieces 
and lyophilised. Lipids were extracted from the tissue 
in a Soxhlet apparatus using different mixtures of chlo­
roform and methanol. The extracted lipids were sub­
jected to alkaline methanolysis to remove alkali-labile 
phospholipids, and silicic acid chromatography to 
remove non-polar lipids (i.e. mainly methyl esters of 
fatty acids). The DEAE-cellulose columns separated 
the acidic glycolipids from the non-acidic glycolipid 
components. In order to remove sphingomyelin the 
sample was acetylated and subjected to silicic acid 
chromatography. Glycolipids having multiple O-acety-
lation sites were first eluted, while sphingomyelin, 
having only one O-acetylation site, was retarded and 
eluted later. The isolated glycolipids were O-deacetyla-
ted and further purified by additional DEAE-cellulose 
and silicic acid chromatography. 
The resultant total non-acid GSL mixture was fur­
ther purified and fractionated on a silicic acid HPLC 
column [68] using chloroform/methanol/water sol­
vent mixtures in linear gradients and a c onstant flow 
rate [68](Paperl-4). Fractions were collected and 
monitored by high performance thin layer chromato­
graphy (HPTLC). The pooling of fractions was b ased 
on information from HPTLC (Paper 1 and 2). In paper 
4 the pooling procedure was in some cases performed 
on the basis of LC"on-flow"NMR identification of 
components. 
A substantial amount of GSL appeared to be lost 
during the final stages of the GSL preparation in the 
pig lung preparation (Paper 4], The silicic acid columns 
were found to irreversible bind (preferentially longer) 
GSLs, w hich normally should be eluted by the polar 
mixture of chloroform/methanol/water in proportions 
40:40:12 (by volume). This have been found by others 
[69] and losses can be diminished to some extent if the 
slowly moving fraction eluted with chloroform/metha­
nol/water (40:40:12) from the initial silicic acid 
column is n ot further processed. This will result in a 
less pure fraction of extended GSLs (often in small 
amounts) which can be derivatised and used for mass 
spectrometry analysis. 
Ceramide glycanase-cleavage of GSLs 
The polar GSL mixtures used for ceramide glycanase 
cleavage were incubated with sodium cholate, sodium 
acetate buffer and ceramide glycanase [70]. After incu­
bation, the product was passed through CI 8 reverse 
phase cartridges in order to remove ceramides and 
potential traces of non-cleaved GSLs [71], The cera­
mide fraction was used to determine the digestion 
yield. The non-adsorbed fraction was analysed by TLC 
and non-digested GSL could be visualised by anisalde-
hyde staining. The glycanase digestions was estimated 
to have an efficiency of more than 90 % (Paper 2,4). 
Thin layer immunostaining 
By using thin layer immunostaining with antibodies 
against carbohydrates, the achieved binding informa­
tion can be used for the assignment of i.e. blood group 
specificity to different GSLs. The chromatographic 
separation on the HPTLC plate also gives information 
related to carbohydrate chain length, +/- one sugar 
component. Both sugar chain length and ceramide dif­
ferences contribute to the chromatographic mobility 
of the GSL. The achieved data are empirical and based 
on prior experience, e.g. references. 
The immunostaining analyses were performed eit­
her by the method of Magnani et al [72, 73] (Paper 1 
and 2) or by the method of Hynsjö et al. [74] (Paper 2 
and 4). Depending on the complexity of the mixtures, 
5-10 (ig of the GSL mixture were applied to HPTLC 
plates. Chromatography was performed using a solvent 
mixture of chloroform/methanol/water in proportions 
60:35:8 (by volume). The anisaldehyde reagent was 
used for chemical detection of the GSLs on the 
HPTLC plates [66]. Monoclonal antibodies (MAb) 
and immunostaining of thin layer plates were used to 
identify blood group related epitopes. The primary 
anti-carbohydrate MAb was detected by labelled 
secondary antibodies, either 125j ancj visualised by 
autoradiography using a y-sensitive film (Paper 1 and 
2) or by alkaline phosphatase labelled antibodies, made 
visible by the catalysis of a colour reaction (Paper 2 
and 4). 
Glycolipid biosynthesis. 
In Paper 1, a biosynthetic study was performed with 
enzymes prepared from pig small intestine epithelial 
cells. The study was made to evaluate the potential of 
prepared enzymes to produce GSL products in vitro 
from the available precursor GSLs and radioactive 
labelled sugar residues (e.g. fuc ose, galactose and N-
acetylgalactosamine) and to compare the result with 
the in vivo expression of GSL structures. 
A crude microsomal fraction was prepared from 
mechanically or enzymatically released epithelial cells 
[75, 76] and was used as the enzyme source. Defined 
precursor glycolipids were incubated with the enzyme 
preparation and radio-labelled substrates (e.g. UDP-
[U- ^C]galactose, UDP-N-acetyl-D-[ 1 -^C]galacto-
samine or GDP-[U-^C]fucose). Tris-HCl, ATP, 
MnCl2 (or MgCl2 depending on assay), NaNj, and 
Triton X-100 was added prior to the incubation [75, 
76]. The products were passed through prewashed 
CI 8 cartridges to trap the glycolipids and separate 
them from the radiolabeled substrates and enzymes 
[76]. The glycolipids (including those, which had been 
radiolabeled by the enzyme reaction) were eluted 
with methanol. HPTLC and autoradiography identifi­
ed the products. 
Glycolipid and oligosaccharide 
preparation for MS analysis 
Permethylation 
Native GSLs and oligosaccharides can be analysed by 
fast atom bombardment mass spectrometry (FAB-
MS), electrospray ionization mass spectrometry (ESI-
MS), liquid secondary ion mass spectrometry (LSIMS) 
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and matrix-assisted laser desorption/ionization mass 
spectrometry (MALDI-MS). However, the sensitivity 
of these methods on native GSL structures is low, bu t 
can be 20-50 fold increased by derivatization [77], 
In order to analyse glycoconjugates and oligosaccha­
rides by EI-MS these molecules have to be derivatized. 
The derivatization increases the volatility and thermal 
stability of the molecules. This is a p rerequisite for EI-
MS analysis. Permethylation was performed using solid 
NaOH in dimethyl sulfoxide and iodomethane accor­
ding to Ciucanu and Kerek [78] as modified by Larson 
et al [79]. The procedure results in a methylation of all 
carbohydrate hydroxyl and amide groups. Permethyla-
ted GSLs and oligosaccharides analysed by EI-MS give 
sequence information due to the formation of oxoni-
um ions (Bj) along the carbohydrate chain. (See figure 
2.) 
Reduction 
The reduction procedure was performed in diethyl 
ether using LiAlH^ [81]. The reduction of GSLs con­
verts amides to amines, which in electron ionisation 
(EI-MS) strongly favours the formation of stable 
immonium ions [imm]+. The ionization occurs at the 
nitrogen of the ceramide and the immonium ions are 
formed by a a-cleavage of the sphingosine base and 
contain the carbohydrate chain together with the fatty 
acid part. The advantage with permethylated and redu­
ced GSLs in EI-MS is that the immonium ions give the 
size of the molecules. This is o ften not the case with 
just permethylated GSLs. (See figure 3.) 
Glycolipid preparation for NMR analyses 
In Pape r 1 and 4, conventional proton NMR was used 
for the characterisation of the GSLs. The native glyco­
lipid fractions were dried and later deuterium 
exchanged in excess of CDCI3/CD3OD, dried again 
and dissolved in a mixture of dimethyl sulfoxide-dg 
containing 2% of D2O. 
Glycolipid preparation 
for LC-NMR analyses 
In Paper 3 and 4, the LC"on-flow"NMR technique was 
used for the GSL analysis. The GSL fractions were 
dried and deuterium exchanged in excess of CDCI3/ 
CD3OD, dried again and dissolved in a mixture of 
CDCI3/CD3OD/D2O. 
Mass spectrometry 
Direct inlet EI+ mass spectrometry 
Permethylated and permethylated-reduced GSLs can 
be analysed by EI-MS using the fractionated evapora­
tion technique (Paper 1). This "in-beam" sample tech­
nique uses a cuvette for sample loading, which is 
brought in close proximity (l-2mm) to the electron 
beam. The ion source temperature is then program­
med from 180 to 360° C to allow the GSL mixture to 
evaporate and be ionized [82], 
High-Temperature Capillary 
Gas Chromatography (GC) 
High-temperature capillary gas chromatography was 
used to analyse oligosaccharides (Paper 2, 4) due to the 
high resolution and sensitivity achieved. The retention 
and resolution of sample components (solutes) in 
capillary GC result from the differential distribution 
(partition) of the solutes between the stationary liquid 
and the mobile gas phases. As a r esult of the solution-
dissolution process of the solute molecules into and 
out of the stationary phase, solute retention and reso­
lution in the column are obtained. The magnitude of 
retention depends on the partition coefficient (K), an 
equilibrium constant, which is d efined as the ratio of 
the concentrations of solutes in the stationary and 
Figure 2. 
Fragment ions in 
El+ mass spectra 
from permethyla­
ted GSLs and oli­
gosaccharides. 
The nomenclature 
is according to 
Domon and 
Costello [80]. 
Reduction 
LiAIH, 
Figure 3. 
Reduction of ami­
des to amines and 
formation of immo­
nium ions by a 
a-cleavage of the 
sphingosine base 
in EI-MS of permet-
hylated-reduced 
GSLs. The "fish­
hooks" half-arrows 
indicate transfer of 
a single electron. 
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mobile phases. The larger the value of the partition 
coefficient for a sample component, the higher solubi­
lity and longer retention in the stationary phase. The 
partition coefficient is related to the column phase 
ratio (ß) and the retention factor (k) by K=ßk. The 
retention factor k is a measure of the retention time for 
a sample component relative an unretarded compo­
nent. The column phase ratio can be expressed as 
ß=Vg/V] =r/2df, where Vg is the gas phase volume, Vj 
is th e stationary liquid phase volume, r is the column 
radius and df is the film thickness. In order to decrease 
k, ß has to be increased since the product (K) is a con­
stant. ß can be increased either by increasing the 
column inner diameter (a wider column] or by decre­
asing the film thickness (dp) o r both. A standard capil­
lary column with a diameter of 0.25 mm and a f ilm 
thickness of 0.25^m has a ß value of 250. A column 
with the same diameter, but with a fi lm thickness of 
0.02 |im has a ß-value of 3125. ß is increased by a fac­
tor of 12.5, which results in a much shorter retention 
time. In our case ultra-thin films were necessary in 
order to Chromatograph the large permethylated oligo­
saccharides. 
For fast analysis at high linear gas velocity the zone 
spreading is decreased by using a c arrier gas with low 
viscosity and high diffusivity such as hydrogen. The 
permethylated oligosaccharides were dissolved in ethyl 
acetate, injected on-column into a gas Chromatograph 
equipped with a flame ionisation detector. A linear 
temperature program from 70 °C to 400 °C was used 
[83], 
High-Temperature Gas Chromatography/ 
Mass Spectrometry (GC/MS) 
High-resolution chromatography and structural infor­
mation can be achieved by using high-temperature gas 
chromatography in combination with mass spectrome­
try (GC/MS) (Paper 2,4). The mass spectra of permet­
hylated oligosaccharides are simple to interpret, as 
they are mainly composed by sequence oxonium ions 
(Bj) and in the presence of HexNAcs inductive ions 
(Zj) (Figure 4). In some cases, information about bin­
ding position can be achieved (e.g. differentiate bet­
ween type 1 and type 2 chains) [84, 85, Teneberg and 
Karlsson, unpublished observation]. The chromato­
graphic conditions were identical to those given above, 
except helium acted as carrier gas a nd constant flow 
mode were used [86]. 
Matrix-assisted laser desorption/ionization 
mass spectrometry (MALDI-MS) 
MALDI-MS (Paper 2 and 4) is used to analyse the 
dynamic mass range of oligosaccharide mixtures prior 
to gas chromatography analysis, as the MALDI mass 
spectrum gives mo lecular ions of the oligosaccharides. 
This gives an indication of the size of the molecules in 
the mixture and the feasibility for GC/MS analysis. A 
thin-film matrix surface was prepared using the fast 
evaporation technique from 2,5-dihydroxybensoic acid 
in acetone doped with 1 OmM LiCl. Permethylated oli­
gosaccharides were dissolved in ethyl acetate and appli­
ed to the matrix surface. Lithium adducts of the mole­
cular ions [M+Li]+ were produced. 
Nuclear Magnetic Resonance 
Proton NMR spectroscopy (^H NMR) 
NMR of native glycolipids was performed in Paper 1 
and 4. Spectra were recorded at 500 MHz at a tempe­
rature of 30 °C (Paper 1) or RT (Paper 4). The chemi­
cal shifts were given relative to tetramethylsilane [87]. 
Liquid Chromatography-Nuclear 
Magnetic Resonance (LC"on-flow"NMR) 
Papers 3 and 4 concern the LC"on-flow"NMR techni­
que for rapid screening and pooling of native GSLs. 
The method is sti ll under development. A LC pump 
with a straight phase silica column was connected on­
line to the NMR probe and GSLs were separated prior 
to 500 MHz NMR analysis using a constant flow gra­
dient in a so lvent of CDCI3/CD3OD/D2O. An UV-
Figure 4. Mass 
spectrum of the 
Hex-O-Hex-O-
HexN-O-Hex-O-
Hex component 
from pig kidney 
[85]. 
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detector for fractionation observation was connected 
in t he interface between the LC and the NMR probe 
head. Continuous flow ^ H spectra were obtained using 
a one-dimensional NOESY pulse sequence providing 
improved solvent suppression. Pseudo-2D spectra 
were obtained using a sine -squared window multipli­
cation prior to Fourier Transformation in the f2-dimen­
sion. The 2D spectra consisted of all obtained ID spec­
tra added in a single plot, with time on the y-axis and 
the chemical shift region on the x-axis. Smaller GSLs, 
which eluted early from the column, were found in the 
Figure 5. 2D 
spectra of the 
slowly moving 
fraction from pig 
lung (Paper 4). 
lower regions of the 2D spectra. Longer and hence 
more polar GSLs were found in the higher regions of 
the plot. The anomeric proton region (5.5-4.0 ppm) 
was used for monitoring the fractionation or elution. 
The 2D spectra showed the dynamics of the gradient 
elution with increasing or decreasing signals from sig­
nificant anomeric protons appearing in the plot. 
(Figure 5). 
The different anomeric protons from the sugar 
chains are indicated in the spectra to facilitate the 
interpretation. 
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3. A presentation 
of present work 
The four papers presented in this thesis are part of a 
wider interest in xenogenic antigens involved in 
human xenotransplantation. 
Paper one is aimed towards understanding carbohy­
drate expression at the level of biosynthesis regulation 
in the pig small intestine. The paper also deals with 
structural characterisation of pig small intestine GSLs 
and in vitro biosynthesis of GSLs with enzymes isola­
ted from the same intestine. 
Paper two shows oligosaccharide expression in 
small tissue specimens from different pig organs of a 
single semi-inbred pig. It demonstrates the quantitati­
ve differences in expression of carbohydrates in the 
organs and discusses their impact as antigens. 
Paper three is a methodology paper describing for 
the first time LC"on-flow"NMR of native GSLs. The 
GSL fractions are separated and identified from the 
obtained spectra and TLC analysis. 
Paper four is a development and an application of 
the LC"on-flow"NMR method described in paper 
three. It is concerned with an uncharacterised GSL 
mixture derived from pig lungs. The LC"on-flow"NMR 
method was used together with GC and GC/MS for 
the characterisation of the GSLs. The NMR method 
was also shown to be useful for pooling of GSL frac­
tions after chromatography. 
Paper 1 
This paper describes the expression of blood group and 
histo-blood group GSLs in the epithelial cells of porci­
ne small intestine, both from a structural and a biosyn-
thetic perspective. We initiated this descriptive study 
to see if the expression of blood group ABH GSLs in 
the pig intestine, similarly as in humans, confined to 
type 1 chains [2, 18]. 
Through biosynthetic studies using crude enzyme 
preparations from pig intestinal epithelial cells and 
known characterised precursor glycolipids, we also 
aimed at some understanding of the glycolipid antigen 
expression on the level of precursor and enzyme avai­
lability and specificity. The paper also contains struc­
tural characterisation of GSLs based on thin layer 
immunostaining, EI+-MS and 'H NMR. 
Non-acidic GSLs were isolated from porcine small 
intestinal epithelial cells, separated by column chroma­
tography and pooled into nine non-polar fractions 
(NP1-9) and five polar fractions (Pl-5)(Paper 1, Figure 
1). Due to the small amount of sample, pooled GSL 
fractions were allowed to contain up to two different 
sugar chain lengths per fraction, which resulted in up 
to four different GSLs being present in a test tube. The 
last polar fraction P5 contained ^7 sugar residue GSLs 
due to the very small amount of sample. TLC and im­
munostaining monitored GSL separation. Proton 
NMR spectroscopy of native glycolipids and EI+-MS 
of permethylated and permethylated-reduced glycoli­
pids were performed. 
The characterisation of GSLs from epithelial cells 
with EI+-MS, ^H NMR and thin layer immunostaining 
showed similarities with earlier published results on 
the human small intestine by Björk et al [18] and 
Holgersson et al [2], Like humans, type 1 chain blood 
group ABH GSL and type 1 and 4 as p recursor chain 
molecules dominate the small intestine GSL expres­
sion. This expression is similar to the human intestine 
expression, except for the lack of A-7-4 in man [2], 
Because only A type 1 structures were found, the 
dominating in vivo precursor used/available must be 
Lc4Cer, which is supported by the in vitro studies. 
The biosynthetic studies were performed with 
crude enzyme preparations from pig intestinal epithe­
lial cells to evaluate the potential of the enzyme mix to 
produce GSLs in vitro with the added available pre­
cursor chains and radiolabelled sugars in the test tube. 
The result was compared with the in vivo expression of 
GSL from the same pig small intestine (Table 2). 
The identification of the product of Lc4Cer + fuco-
se (Paper 1, Figure 5, Lane 1) was performed by TLC 
migration following acetylation. Since both H-5-1 and 
Lea-5 are possible products in the Lc^er + fucose 
experiment, (the fucose is bound to the terminal Gal 
in an al,2 position for H-5-1, compared to a al,4 lin­
kage to the subterminal GalNAc for Lea-5], an acety-
lated pure fraction of each of these references was also 
tested by TLC. The difference in chromatographic 
mobility allows product identification on the TLC 
plate. The product chromatographed like acetylated 
H-5-1 (Paper 1, Figure 6a-b). The same experiment 
was performed with nLc4Cer + fucose (Paper 1, Figure 
5, Lane 2) which could form as a product either H-5-
2 or Lex-5 (Fucal,2 to terminal Gal for H-5-2, and 
Fucal,3 to subterminal GalNAc for Lex-5). The ace­
tylated product migrated similar to acetylated H-5-2 
(Paper 1, Figure 6c-d). 
The product formed by LcgCer + galactose 
(Paperl, Figure 7a) migrated as a triplet band on the 
Table 2. The result 
of the in vitro bio­
synthetic studies 
with microsomal 
enzyme fractions, 
radioactive labelled 
sugars and 
precursor chains. 
Precursors GDP-[U-14C] 
fucose 
Precursors UDP-N-acetyl-
D[1-14C] 
galactosamine 
Precursors UDP-pj-
^4C]galactose 
Lc4Cer + H-5-1 + LcgCer + 
nLc4Cer + H-5-2 + GggCer 
-
Gg4Cer + H-5 on Gg4 + 
GbgCer + H-6-4 + 
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thin layer pla te. The references used created different 
chromatographic patterns, as in the cases for H-5-1 
and Lea-5, which allowed identification on the TLC 
plate. Pure Lc^Cer was found to migrate as a doublet 
band in the same region, ß-galactosidase specific for 
Galßl,4 cleavage was used to treat the product, and 
the purified mixture was applied to TLC. The treat­
ment resulted in a loss of the lower band and about 
50% of the middle band of the triplet (Paper 1, Figure 
7b). The experiment was repeated and the product 
now counted in a ß-scintillator. The enzyme cleaved 
off 40% of the radioactivity. 
Immunological reactivity was found to the blood 
group A GSLs based on all f our chain types with the 
type 1 chain hexaglycosylceramide being predomi­
nant. A-6-1 was how ever clearly dominating, as asses­
sed by TLC and was also the only component detected 
in that molecular size interval by EI+-MS and 
NMR. Thus, the dominating in vivo precursor used 
should be Le^er. This was also in agreement with our 
identification of the precursor Lc4Cer, and the appa­
rent absence of the nLc^Cer precursor. Furthermore, 
this was also s upported by the in vitro studies , which 
showed that all precursor chains (Lc^Cer, nLc^er, 
Gg4Cer, GbgCer) could serve as precursors for fucose 
with the enzymes prepared from the pig small intesti­
ne. The in vitro bio synthetic studies with blood group 
H GSLs based on the four precursor chains used (H-5-
1, H-5-2, H-5 on Gg4Cer and H-6-4), showed that all 
could serve as acceptors of GalNAc to produce blood 
group A structures with the enzymes prepared. 
Lc3Cer can, in our biosynthetic studies, using enzy­
mes isolated from the pig, form both Lc4Cer and 
nLc4Cer. However, only Lc4Cer could be identified in 
the pig small intestine epithelial cells by immunostai-
ning, MS and 1H NMR as mentioned earlier. The appa­
rent absent of nLc4Cer was established by probing 
TLC plates with anti-Galßl ,4GlcNAc MAbs (Paper 1, 
Figure 2a-b). These results are in contradiction with 
our in vitro studies where we could see a conversion of 
LcjCer to nLc4Cer. The in vitro situation may howe­
ver be explained by a different localisation in the Golgi 
apparatus. 
The ßl,3galactosyltransferase in turn could loose its 
in vivo specificity when it is extracted from its envi­
ronment within the intact cell and be able to add 
galactose also in a ßl ,4 position in vitro. This could also 
account for the lack of specificity seen for the 
al,2fucosyltransferase and al,3fucosyltransferases as 
well. A non-specific ß-galactosidase specificity is less 
possible, because the high specificity for the Galßl,4 
linkage of the ß-galactosidase was established during 
the development of the method. 
Paper 2 
GC/MS was used in the second article for rapid scree­
ning of GSL structures in small samples from kidney, 
spleen, small intestine, liver, salivary gland and heart 
from a single pig of a semi-inbred pig strain. The car­
bohydrate based blood group antigen distribution with 
special reference to GSLs with terminal Gala expres­
sion was characterised by MALDI-MS, GC, GC/MS 
and thin layer immunostaining. 
Terminal Gala carrying GSLs in the pig is of parti­
cular interest for human xenotransplantation (trans­
plantation between different species, see chapter 4 
Xenotransplantation), where these antigenic structures 
have been shown to be involved in hyper acute rejec­
tion (HAR) when attempting to transplant across the 
species barrier i.e. pig organs to humans. The 
Galal,3Gal epitope is not present in humans and hig­
her primates but is present in most other species. 
Humans have also preformed circulating antibodies to 
these structures. This antigen and the preformed anti­
bodies are responsible for the immediate HAR of 
xenotransplanted organs. 
Characterisation of GSLs was performed by 
MALDI-MS, GS and GC/MS. GC/MS is a very sensi­
tive method, which can be used for small samples and 
can be contrasted with full-scale preparation and con­
ventional GSL analysis. P icomoles of components in 
the GSL mixture were found to be sufficient for ana­
lysis and gave clear and interpretative mass spectra. 
Due to the small sample amounts, no ^H NMR was 
used for structural identification. Instead, thin layer 
immunostaining, GC and MALDI-MS were used to 
determine basic structural identities. We were able to 
interpret structural identity for the oligosaccharides 
present by combining the acquired information from 
our experiments with studies by others. 
Total GSL fractions and the slower moving fractions 
^4 sugar GSLs) from kidney, sp leen, small intestine, 
liver, salivary gland and heart were used for thin layer 
immunoanalysis. Staining with antibodies specific for 
the Galal,3 epitope detected five-sugar compounds in 
kidney, salivary gland and heart, and a six-sugar com­
pound in kidney and heart. Additional staining of 
eight- and ten-sugar Gala- components could also be 
seen in the organs. The findings were confirmed by lec­
tins reactive against Gala- epitopes that bound to 
compounds in the five/seven sugar region on the TLC 
for the kidney and heart. An anti-A reagent bound to 
six- and seven sugar compounds in the salivary gland 
and heart. 
Oligosaccharides cleaved off from the GSLs in the 
slowly moving fractions were characterised by 
MALDI-MS, GC and GC/MS. MALDI-MS gave infor­
mation about the dynamic mass range of the fractions, 
GC was used to screen the number of components in 
the mixture and GC-MS gave sequence information of 
the oligosaccharide components. 
The characterisation revealed high concentrations 
of a fiv e-sugar oligosaccharide with terminal hexose, 
probably galactose, in all organs, earlier indicated by 
thin layer immunostaining. The structures were identi­
fied as G alal,3nLc4Cer which is in accordance with 
others [88], The kidney also revealed a six sugar ter­
minal Hex (Gal) component consistent with Gala 
l,3LexCer [89], 
Limited linkage information can be achieved using 
high temperature GC/MS in situations where conven­
tional linkage analysis techniques, such as ^H NMR 
and degradation can not be used. The high resolving 
power obtained by GC using ultra thin films was used 
for demonstration of the partly resolved oligosacchari­
des derived from H-5-2 and H-5-1. The oligosacchari­
de isomers could be differentiated on basis of their 
mass spectra due to relative intensity differences of the 
fragment ions at m/z 182 and m/z 228 since the iso­
mers were chromatographically separated. This infor­
mation also gave us the possibility to identify the blood 
group A hexasaccharide based on the type 1 chain in 
the salivary gland and heart together with its characte­
ristic sequence fragment ions (Bj, B2 and B3, see chap-
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ter 2) and the indication by anti-A MAbs. 
Conventional GSL preparation and analysis can be 
compared with the small scale preparation and analy­
sis invol ving thin layer immunostaining, MALDI-MS, 
GC and GC/MS used in this paper. The small-scale 
preparation and analysis appear to have an advantage 
when organs from a single animal are to be analysed, 
e.g. in intra-individual studies. The methods allow dif­
ferent parts from an organ to be separately analysed. 
Small tissue specimens (10-140 g) can be used instead 
of kilograms. GC separation makes it possible to analy­
se individual components of a mixture when coupled 
to MS. Another advantage is that acidic and non-acidic 
components could be analysed simultaniously with the 
above techniques. 
The kidney is rich in GSLs containing terminal Gal( 
residues such as Galal^nLc^Cer and Galal,3LexCer 
[88, 89], The high Galal,3 content in the pig kidney 
may indicate problems of HAR because of pre-existing 
antibodies which react well against this epitope, and 
thus make it a less suitable organ for pilot xenotrans­
plantation experiments. There are indications of exten­
ded Galal ,3nLc4Cer structures in the pig heart, 
which probably will give the same immune reaction as 
the shorter ones. The complex Gala- GSL expression 
of the heart suggests similar problems as are seen with 
the kidney, or even worse, since they are more accessi­
ble for antibodies. The liver, small intestine and saliva­
ry gland show the lowest amount of Gala- expression 
on GSLs. 
Paper 3 
The third and fourth papers evaluate LC"on-
flow"NMR separation and analysis of native GSLs. The 
aim of Paper 3 was to evaluate the possibility of using 
the LC"on-flow"NMR technique to separate native 
GSL mixtures and also obtain interpretative spectra. 
Three pure GSL components from human A] ery­
throcytes were pooled together. The criteria for suita­
ble GSLs for the experiments were 1) well characteri­
sed different components, 2) easy GSLs to resolve by 
column chromatography, 3) present in sufficient 
amounts and 4) a presence of both a- and ß-anomeric 
protons. LcCer (Galßl,4Glcßl,lCer), GbßCer (Gala 
l,4Galßl,4Glcßl,lCer), and Gb4Cer (GalNAcß 
l,3Galal,4Galßl,4Glcßl,lCer) fulfilled these crite­
ria. 
A straight-phase silica column was interfaced to the 
NMR instrument. The sample mixture was injected on 
the column, and a g radient system of deuterated sol­
vents (e.g. CDCI3/CD3OD/D2O) with an increasing 
polarity was used. Provided optimal conditions, a sepa­
ration of the GSLs were achieved. The NMR probe 
recorded continuous "on-flow" spectra during the 
experiment. NMR spectra were recorded for each 
component during the period the GSL was inside the 
probe. The fractions were collected and monitored by 
TLC after the LC"on-flow"NMR analysis. 
The results were presented in a 2D contour plot, 
showing the time and dynamics of the separation on 
the y-axis and the chemical shifts on the x-axis (Paper 
3, Figure 2). The coarse of separation could be follo­
wed on the y-axis, starting with the earliest eluted 
GSL, lactosylceramide, in the lower region of the plot. 
As t he solvent became more polar, the longer, more 
polar globotriaosylceramide and later globotetraosylce-
ramide were eluted and entered the NMR probe. 
These extended GSLs are found in the top region of 
the 2D plot. 
We found the LC"on-flow"NMR technique to be 
useful for native GSL separation and also resulted in 
interpretative spectra if large amounts of sample 
(about 300|ig of each component) were present and 
the GSL were separable on the column. The chemical 
shifts tended to drift when a more polar solvent was 
introduced into the system, which complicated the 
interpretation of more complex GSLs. 
Paper 4 
In the last paper, the LC"on-flow"NMR technique was 
used for separation, screening and characterisation of 
an unknown mixture of native GSLs. The information 
obtained was intended to assist pooling of the genera­
ted GSL fractions. We also wanted to evaluate the limi­
tations of the method regarding GSL separation, ana­
lysis and detection. The paper includes thin layer im­
munostaining, MALDI-MS, GC and GC/MS of relea­
sed oligosaccharides, used to assist in the structural 
interpretation as described in chapter 2. As part of the 
analysis, the LC"on-flow"NMR spectra were compared 
with conventional ' H NMR spectra from the GSL 
fractions obtained. 
GSLs from 4 pig lungs were prepared [66]. The 
fraction contained GSLs in different amounts and of 
different chain length (e.g. up to 5 sugar GSLs). The 
mixture was injected onto the column, which was 
interfaced with the NMR probe. A solvent gradient of 
CDCI3/CD3OD/D2O with an increasing polarity was 
used for the silicic acid column separation. Smaller, less 
polar GSLs were the earliest eluted and entered the 
NMR probe first. With increasing polarity, longer and 
more complex GSLs entered the probe. NMR spectra 
were recorded "on-flow" during the run and were pre­
sented in a pseudo 2D plot (see Figure 5). 
Since the obtained spectra contained solvent infor­
mation and in some cases showed signal drift, conven­
tional ' H NMR was prepared on the separated frac­
tions. At this early state of LC"on-flow"NMR develop­
ment the 1H NMR was used for reproduction and con­
firmation of the LC-NMR spectra findings. These spec­
tra were interpreted and compared to the LC-NMR 
screening and also compared with reference spectra to 
give structural confirmation. The spectra were also 
used to evaluate signal drift and exclude false signal 
interpretation due to solvent interference. MALDI-MS 
gave the dynamic mass range for the prepared oligo­
saccharides deriving from the GSLs. The gas chroma-
togram gave an appreciation of the number and 
amount of components in the mixture. The different 
retention times also gave an indication about the rela­
tive size of the molecules. GC/MS gave sequence 
information by the oxonium ions (BJ detected from 
the oligosaccharides. The thin layer immune staining 
with different MAbs recognised GSLs with antibody 
defined epitopes. 
Since the techniques used complement each other, 
the generated information was combined and used 
together for structural characterisation. Some thin 
layer immunostaining results are shown in Table 3 {for 
a total s ummary, see Paper 4, Table la-b). 
The characterised oligosaccharides from GSLs in 
the slowly moving fraction are presented in Table 4. 
For the first time, the Galal,3nLc4Cer structure was 
identified and reported in pig lung. A quantitative 
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Antibody specificity Binding Binding region 
on the TLC. Esti­
mated number of 
sugars in the carbo­
hydrate chain 
anti-H-2 + 5,7 
anti-Le^H ( H type 1) + 5 
anti-Galal,3 + 5,6 7/8 10/12 
anti-B + 5 
TIC 
peak 
Interpreted 
GSL 
structure 
Structure M Pa): 
1 Gb3 Hex-O-Hex-O-Hex 658.4 
2 nLcg/Lcg HexN-O-Hex-O-Hex 699.4 
3 Gb4 HexN-O-Hex-O-Hex-O-Hex 903.5 
4 nLc4 Hex-O-HexN-O-Hex-O-Hex 903.5 
5 H-5-2/ H-5-1 dHex-O-Hex-O-HexN-O-Hex-O-Hex 1077.6 
6 Galal,3nLc4 Hex-O-Hex-O-HexN-O-Hex-O-Hex 1107.6 
Table 3. Results from thin layer immunostainings of pig 
lung fractions with MAbs by the method of Hynsjö et al 
[74]. 
dominating expression of GSLs of the globo-series was 
also found, which is in accord with other studies of EC 
rich pig tissues e.g. aorta [90], 
Since the GSL composition required a more polar 
gradient of the deuterated solvents (cp. Paper 3), a pro­
nounced signal drift of the GSL protons and solvent 
signals were recorded. Another drawback was the dis­
covery of a loss of l onger GSLs (the longest GSL con­
tained five sugars). 
We also evaluated the possibility to use the LC"on-
flow"NMR technique for guidance when pooling frac­
tions after chromatography. 
TLC analysis is based on the chromatographic 
mobility on the silicic acid on the plate, and can be 
empirically compared to known references. Sugar- and 
ceramide differences can increase or decrease the 
mobility of the GSLs, which can complicate identifi­
cation. Continuously recorded NMR spectra give 
instead signals from i.e. anomeric protons, the infor­
mation being absolute and both qualitative and quan­
titative. In this way, using the a- and ß- signals that 
are easily identified together with their quantitative 
dynamics during separation, even gives us a possibility 
to discriminate between different components that are 
not totally separated over the column. An advantage 
with TLC is that small sample quantities are required 
compared with the large amounts required by LC-
NMR. However, the small amount of GSL applied on 
the TLC is consumed, compared to no loss or destruc-
Table 4. The oligosaccharide structures released from 
GSLs in the slowly moving fraction from pig lungs as iden­
tified by 1H NMR, GC/MS and MALDI-MS. 
tion of the sample after LC-NMR analysis. When the 
LC-NMR analysis is completed, the separation is also 
complete and spectra are obtained. In contrast TLC 
analysis is made after the chromatographic separation, 
and MAbs may take several hours (depending on the 
technique used) to return a result on the epitopes pre­
sent. Furthermore, TLC immunostaining only produ­
ces results related to the specificity of antiserum or 
lectin used. TLC is still a very valuable and cost effec­
tive technique. Regarding LC-NMR, the time consu­
ming steps during a preparation procedure may be 
minimised by LC-NMR and in this way saving money. 
Also, LC-NMR accessories can now be considered 
standard NMR instrumentation and can be comple­
mented with a final on-line MS detector. 
The LC"on-flow"NMR technique can be summari­
sed as follows. The technique can be used for pooling 
and characterisation of GSLs. The sensitivity of the 
technique is low compared with GC and GC/MS, but 
compared to conventional ' H NMR the sensitivity is 
reasonable. For example, GC and GC/MS could easily 
detect nLcjCer but not conventional NMR. Validation 
by 1H NMR is important for the development of the 
LC"on-flow"NMR technique. MALDI-MS, GC, 
GC/MS and thin layer immunostaining together allow 
structural characterisation of unknown GSLs in a mix­
ture. In addition, the structural information showed 
the presence of a Galal,3nLc4Cer GSL not previous­
ly shown in pig lung. 
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4. Xenotransplantation 
Introduction 
A transplantation where the species barrier is crossed 
is usually called xenotransplantation. Two types of 
xenotransplantations have been defined in the literatu­
re, the concordant and the discordant transplantation. 
Usually the two types are referred to as a c losely rela­
ted species transplantation for the concordant model 
(e.g. ba boon to human) and transplantation between 
distant related species for the discordant (e.g. pig to 
human) [91]. The terms are used to distinguish bet­
ween two clinical states of xenograft rejection. In the 
discordant model there is an immediate hyper acute 
rejection (HAR) due to the presence of pre-existing 
antibodies in the host, while in the concordant model 
the graft is initially accepted but will probably be 
rejected over time by host immune responses. There 
are several factors that can contribute to an organ 
transplant rejection, for example mismatched blood 
groups or the susceptibility of specific organs to acute 
rejection. Kidneys are usually easily hyperacutely 
rejected while the liver seems to be relatively resistant. 
Hyperacute rejection 
HAR leads to typical clinical signs of a vascular rejec­
tion with oedema, haemorrhage and infarction with 
thrombosis in the organ vessels [92].The expression of 
the Gala- antigen is heterogeneous within different 
organs, with preferential, non-homogenous expression 
in small vessels [93]. HAR is considered to be caused 
by preformed, xenoreactive natural antibodies (XNA) 
in the recipient species reacting with antigens exposed 
on the endothelium in the donor's organ vessels. 
Microscopically, the event is characterised by com­
plement activation (via the classical pathway), endot­
helial cell activation, platelet aggregation [94, 95], 
extravasation of white blood cells [96] and a perturbed 
endothelial layer [97]. 
Antibodies and antigens 
XNAs are found in all animals. In the pig to human 
xenotransplantation situation, human XNAs, reactive 
with xenogenic pig antigens are directed against anti­
gens of carbohydrate origin. The major antigens invol­
ved express the carbohydrate Galal,3Gal epitope [98] 
that is due to expression of the gene encoding the al,3 
galactosyltranferase (al,3 GT). In humans and Old 
World monkeys, apes and chimpanzees the Galal,3 
antigens are not expressed due to inactivation of the 
(al,3 GT) glycosyltransferase. The Gala- carbohydra­
te epitope is expressed on both lipids and proteins. 
GSL expression shows great variation in different 
organs of the pig, with e.g. an increased expression in 
the heart and the kidney and decreased expression in 
the small intestine and the liver [85]. 
Endothelial cell (EC) activation by the immune sys­
tem is at the centre of HAR, in part because of the ECs 
location in the blood vessels. The ECs actively contri­
bute to the rejection process by promoting pathologi­
cal changes, which lead to the acute graft failure [99]. 
EC activation is thought to be initiated by the com­
plement factors (e.g. C 5a) and the membrane attack 
complex (MAC). 
Different approaches to avoid HAR 
Reduction of the Galal,3Gal expression 
How can HAR be avoided? No one knows for sure that 
the reaction can be avoided entirely, but many results 
show a d ecrease and a slower rejection when modify­
ing the donor organs or the host's immune response. 
Donor organ animals can be modified in several ways; 
genetic modification of the biosynthetic pathway 
responsible for Galal,3Gal expression by introducing 
competing transferases e.g. an al,2FT [100] or by 
introducing human complement regulatory proteins 
[101]. Knockout techniques which turn-off a specific 
gene [102] and hydrolase treatment of the pig organs 
which destroys the undesired antigen are other ways 
tested to decrease HAR. These experiments do not 
show a 100% reduction of HAR, but in some cases, up 
to 70% in reduction has been achieved [100], The 
"ideal situation" would be non-HAR animals whose 
organs are suitable for grafting to humans and which 
do not express the Gala- epitopes. These animals do 
not exist naturally and are very difficult to produce. 
With regards to the pig, which is a mammal residing 
high up in the evolutionary tree, probably has a range 
of al,3GT in the cells, the knockout technique will be 
very difficult. If the knockout technique succeeds in 
eliminating one Gala glycosyltransferase, potentially 
another al,3GT could still Gala- glycosylate the 
organ. No one knows how many knockouts would be 
required to eliminate the Galal,3Gal epitope from 
the pig. Hydrolase treatment is thought to reduce the 
level of Galal,3Gal epitopes expressed on the EC, but 
the treatment is only temporary as the antigens are 
known to reappear on the surfaces after a shorter time 
span. 
Manipulation of the immune response 
Manipulation of the host is an alternative approach to 
reduce HAR. This can be done by immunosuppressive 
drugs, or by absorption of the antibodies involved in the 
rejection. Immunosuppressive drugs are commonly 
used after allotransplantation and combinations of the 
drugs have been used in the xenotransplantation situa­
tion. Xenotransplanted patients probably need more 
specific other types and perhaps more intensive immu­
nosuppression than allotransplanted patients do, due to 
the fact that the immune response to xenotransplanta­
tion is probably stronger than in allotransplantation 
[97]. HAR leads directly to T cell activation by the por­
cine presenting cells which expresses the pig antigens in 
significant amounts on the endothelium. Human MHC 
class II r estricted T cells also recognise this pig antigen 
exposure, and participate in HAR [99]. The matching 
of pig organs to the recipient is primitive compared to 
allotransplants, which show good host-matching and 
low expression of foreign epitopes. A problem in xeno­
transplantation is that the heavily immunosuppressed 
host also is e xposed to microbial agents which include 
those of pig origin, such as bacteria and endogenous 
retrovirus agents or possibly even prions. The concern 
that xenotransplantation may carry the potential for a 
new epidemic has been highlighted by recent experien­
ces with both bovine spongiform encephalopathy and 
human immunodeficiency diseases [103]. 
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Reduction of antibodies 
The reduction of human anti-pig antibodies before 
transplantation is another way of trying to prevent 
HAR. This could be done more or less specifically and 
can be accomplished by pre-transplant organ perfu­
sion, plasmapheresis [63, 104], or by circulating the 
blood from the recipient extracorporally through affi­
nity columns, prior to transplantation, which bind 
human immunoglobulins [105, 106]. Different absor­
bents can be used, but protein A or immunoglobulin-
binding antibodies are most commonly used in such 
columns [105, 106]. 
A more specific absorption of xenoreactive pig anti­
bodies can be achieved by perfusing the blood through 
columns expressing the Galal,3Gal disaccharide 
[107]. However, as shown in Paper 4 [85] and by 
others [89], Galal,3-terminated structures can be 
attached to core chains other than those of the com­
mon Galili antigen, e.g. Galal,3nLc4, in the porcine 
tissues. The porcine al,3 GT is probably responsible 
for the biosynthesis of a spectrum of Galal ,3 contai­
ning immuno dominant epitopes. It is also possible 
that the human antibodies directed against the reper­
toire of pig antigens can distinguish between these dif­
ferent epitopes, just as there are antibodies that can 
distinguish between blood group A determinants carri­
ed by different core saccharide chains [ 108]. An effici­
ent absorber of human anti-pig xenoreactive antibodi­
es should therefore contain a variety of Galal,3-ter-
minated structures in order to absorb as much human 
anti-pig al,3 determined antibodies as possible [109], 
Function of Galai,3Gal? 
The function of the Galal ,3Gal epitope in the pig is 
not yet known. Humans can do without it, but can the 
pig? Reports on mice with an inactivated al,3GT 
gene, found that these mice are viable and have normal 
organs but develop cataracts [102], If thi s also is true 
for the pig is yet to be determined. 
Delayed Xenograft Rejection 
When HAR is avoided, delayed xenograft rejection 
(DXR) can still occur. DXR can be averted or delayed 
either by removing and suppressing XNAs and other 
humoral factors, or by depleting inhibiting comple­
ment components. DXR is characterised by abnormal 
thrombo regulation, donor organ EC activation, and 
infiltration of host monocytes and natural killer cells in 
the graft [97]. The cell infiltration (with cytokine pro­
duction), together with EC activation (with an up-
regulation of adhesion molecules, pro-coagulant pro­
teins and production of cytokines), promotes intra-
graft inflammation and thrombosis which are believed 
to be the major mechanisms behind the DXR [110]. 
DXR in xenotransplanted laboratory animals [59] 
shows some similarities with the chronic rejection 
[110] seen after allotransplantation in humans. 
The role of accommodation 
The role of accommodation of the transplanted organs 
despite circulating antibodies in the bloodstream, have 
been discussed [92], Accommodation is defined as the 
survival of an organ graft in the presence of anti-graft 
antibodies and complement. Allotransplantations of 
ABO incompatible kidneys have shown that removal 
of donor antibodies from the recipient could increase 
graft survival, even if the antibodies returned. The 
same phenomenon can be seen in xenografting, though 
not as frequent [92, 111], 
Other considerations 
Many questions still needs to be answered before 
xenotransplantation is an alternative to allotransplan­
tation. One is if the xenotranplanted organs will func­
tion in humans. When the pig was chosen as a model 
animal donor, it was chosen because of its physiologi­
cal and biochemical similarities to human. There are 
similarities, but the differences between the two speci­
es are in majority [112]. Just to examplify, how will 
organs adapt when transplanted to humans considering 
the much shorter life span of the pig (8-10 years)? Or, 
if a pig kidney or liver is transplanted to a human, will 
the enzymes from the pig organ function in the human 
body, and in turn, can or will the human control 
mechanisms and hormones affect the pig organ? Some 
enzymes are found to function, but others do not as in 
the case of human anti-diuretic hormone (hADH) 
[112], Without ADH controlling the urine production 
of the pig kidney it will produce excessive amounts of 
urine which may result in physiological problems or a 
dependency on drug control. Other questions regar­
ding pig physiology like organ size, horizontal organ 
position and blood pressure will also need to be consi­
dered [112]. Also the risk for bacterial and/or virus 
transmission [113] and foreign protein antigens have 
to be considered. 
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5* Final comments 
and future prospects 
As mentioned earlier, the ideal theoretical solution to 
HAR in the pig to human xenotransplantation situa­
tion is a pig donor with al,3 GT knocked out. This 
animal does not yet exist due to difficulties to grow 
proper pluri-potent stem cells. However, the knock­
out technique have earlier produced transgenic mice 
and should, in principle, be useful on pigs too. It might 
just be a matter of time before a Galal,3Gal deficient 
pig exist. Though, is this the solution of HAR? 
Serious doubts have recendy been put forward from 
a population risk perspective. It has been postulated 
that the loss of Galal,3 expression in man might be an 
evolutionary advantage for protection against retrovi­
rus transfer. When a virus particle is pr oduced in e. g. 
the pig, the Gala- antigen is incorporated in its mem­
branes. If the virus particle tries to enter a human, it 
will immediately be destroyed, since humans have 
naturally occurring circulating anti-Gal antibodies. 
In this perspective, it might be advantage to think in 
terms of accommodation, a p henomenon earlier men­
tioned in chapter 4. This reaction has been studied in 
ABO incompatible organ transplantation. The pheno­
menon refers to a state of tolerance, where both anti­
gen and antibodies are present, though without elici­
ting HAR. Several conditions contribute to induce 
accomodation. In the allotransplantation situation 
there is a low concentration of cell surface antigens 
present (as in the case of blood group A2 to O kidney 
transplantation). A low concentration of specific anti­
bodies in serum, achieved through plasmapheresis or 
specific/non-specific immunoabsorption, is also a pre­
requisite. 
In the xenotransplantation situation, as well as in 
allotransplantation, there is a need for screening of low 
antigenic expressing organs. Screening of different 
organs may select for individuals showing a natural or 
genetically manipulated weak Gala- expression. If pig 
organs, transgenic for complement regulatory proteins 
(e.g. DAF), will be used for transplantation there is still 
a need to control differences in carbohydrate antigen 
expression in order to avoid HAR. 
The methods used and/or developed in this thesis 
(e.g. GC/MS and LC"on-flow"NMR), might be the 
methods of choice for these comparative screening 
experiments. GC/MS will then be chosen for its high 
resolving and rapid screening which gives both qualita­
tive and quantitative information and LC"on-
flow"NMR for its quick and reproducible preparation 
of relevant antigen fractions. The qualitative aspect is 
important due to the varying expression of Gala- car­
rier chains/molecules. Both organ- as well as individu­
al differences exist. The quantitative aspects of expres­
sion are important both in xenotransplantation and in 
allotransplantation. Different individual/organ antigen 
profiles may require specially tailored immunoabsorp­
tion columns with a very specific and appropriate solid 
phase to ensure a complete and specific removal of 
cytotoxic antibodies. 
There is still a long way to go before the mysteries 
of xenotransplantation are solved. By the characterisa­
tion of carbohydrates on cell surfaces in organs of 
interest, we take a small, but important step in furthe­
ring our understanding of the mechanisms of xeno-
transplant rejection. 
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